Methimazole (MMI) is an anti-thyroid drug used in the treatment of chronic hyperthyroidism. There is, however, some debate about its use during pregnancy as MMI is known to cross the mammalian placenta and reach the developing foetus. A similar problem occurs in birds, where MMI is deposited in the egg and taken up by the developing embryo. To investigate whether maternally derived MMI can have detrimental effects on embryonic development, we treated laying hens with MMI (0.03% in drinking water) and measured total and reduced MMI contents in the tissues of hens and embryos at different stages of development. In hens, MMI was selectively increased in the thyroid gland, while its levels in the liver and especially brain remained relatively low. Long-term MMI treatment induced a pronounced goitre with a decrease in thyroxine (T 4 ) content but an increase in thyroidal 3,5,3 0 -triiodothyronine (T 3 ) content. This resulted in normal T 3 levels in tissues except in the brain. In chicken embryos, MMI levels were similar in the liver and brain. They gradually decreased during development but always remained above those in the corresponding maternal tissues. Contrary to the situation in hens, T 4 availability was only moderately affected in embryos. Peripheral T 3 levels were reduced in 14-day-old embryos but normal in 18-day-old embryos, while brain T 3 content was decreased at all embryonic stages tested. We conclude that all embryonic tissues are exposed to relatively high doses of MMI and its oxidised metabolites. The effect of maternal MMI treatment on embryonic thyroid hormone availability is most pronounced for brain T 3 content, which is reduced throughout the embryonic development period. Key Words " methimazole " thyroid hormone " chicken " development " brain Journal of Endocrinology (2013) 218, 105-115 Journal of Endocrinology
Introduction
Untreated hyperthyroidism in pregnant women increases the risk for a number of adverse outcomes for the mother and foetus, including intrauterine growth restriction, miscarriage, preterm delivery, pre-eclampsia and congestive heart failure (Luewan et al. 2011) . Maternal hyperthyroidism can be treated with anti-thyroid drugs such as propylthiouracil (PTU) and methimazole (MMI). However, these drugs may in turn have a negative impact on foetal development as they can cross the placenta. The present clinical guidelines advise to avoid the use of MMI in early pregnancy because it may increase the risk of specific malformations including choanal and oesophageal atresia and aplasia cutis congenita (Wolf et al. 2006 , Azizi & Amouzegar 2011 , Rodriguez-Garcia et al. 2011 , Vissenberg et al. 2012 , but it remains unclear whether these abnormalities are linked to MMI or to the maternal hyperthyroidism itself (Barbero et al. 2008) .
While it is known that MMI is transferred from the mother to the embryo/foetus, either through the placenta in mammals or through a deposit in the egg in nonmammalian vertebrates, data on the relative MMI concentrations in different embryonic/foetal tissues are scarce. In addition, to what extent maternal MMI reaching the embryo/foetus is present in the reduced or oxidised form has hardly been investigated. While oxidised MMI metabolites are no longer active as anti-thyroid drugs, they have been associated with cytotoxic effects (Kedderis & Rickert 1985 , Laurence et al. 1998 , Heidari et al. 2012 and as such they may still disturb normal development.
It also remains unclear to what extent maternal MMI treatment disturbs thyroid hormone (TH)-dependent development in the embryo/foetus. Maternally derived MMI can block the developing thyroid gland as shown repeatedly in rats (Comer & Norton 1985 , Ruiz de Ona et al. 1988 , Calvo et al. 1990 ). However, the early vertebrate brain is highly dependent on adequate 3,5,3 0 -triiodothyronine (T 3 ) availability, and it may not yet be able to compensate for a reduced TH supply by an increase in type 2 iodothyronine deiodinase (D2) activity as observed in the adult brain (Ruiz de Ona et al. 1988 , Van Herck et al. 2012 . Apart from inhibiting TH production, it has been found more recently that MMI may also have local anti-thyroid effects in tissues by directly suppressing transcriptional activities mediated by T 3 and its receptors (Moriyama et al. 2007) .
In this study, we have used the chicken embryo to study the effect of maternal MMI treatment on the developing embryo. It has been shown earlier that MMI is taken up from the egg by the embryo and is capable of disturbing development, including brain development (Iqbal et al. 1987 , Liu & Porter 2004 , Kagami & Nishigori 2010 . We measured the levels of MMI and its metabolites in different maternal and embryonic tissues and studied the effect of MMI treatment on thyroxine (T 4 ) and T 3 availability in these tissues.
Materials and methods

Animal treatment and tissue sampling
Experiments were performed on broiler breeder hens (Ross, Belgabroed, Belgium) that were w30 weeks old. They were fed a standard diet with iodine content within the advised range for euthyroidism (1.9 mg/kg). The animals were divided over six pens, with each containing 20 hens and 3 roosters. Those in four pens were treated with 0.03% 1-methyl-3H-imidazole-2-thione (methimazole, Acros Organics, Geel, Belgium) in the drinking water, while those in two pens served as controls. This dose was based on literature data from studies carried out in rats and chickens aimed at inducing hypothyroidism (Iqbal et al. 1987 , Calvo et al. 1990 , Rosebrough et al. 2006 , Sharlin et al. 2010 . The animals were treated for a total of 16 weeks, and we started collecting eggs after 6 weeks of treatment.
Eggs were incubated in a forced draft incubator at 37.5 8C and 50% relative humidity and automatically turned at a 458 angle every hour. The day on which incubation was started was called day 0 (E0). After 6, 14 and 18 days of incubation (E6, E14 and E18), eggs were opened, and the following tissues were sampled: head and trunk at E6; liver, heart, lung, muscle and brain at E14 and E18. Brain was divided into telencephalon, diencephalon, mesencephalon, cerebellum and hindbrain. Tissue samples were immediately frozen in liquid nitrogen and stored at K80 8C for later use.
At 10, 14 and 16 weeks of treatment, a number of nonincubated eggs were sampled for MMI measurements. Egg yolk and egg white were separated and stored frozen until MMI analysis.
Treatment was stopped for all animals after 16 weeks, and ten control and ten MMI-treated hens were killed at that moment to collect their liver, kidney and different brain regions.
Prior to tissue sampling, blood samples were collected from hens and from E14 and E18 embryos in heparinised tubes. After centrifugation, plasma was stored at K20 8C until analysis.
The Ethical Committee for animal experiments of the KU Leuven approved all the experimental protocols.
Determination of MMI levels
The method for the determination of reduced and total MMI levels was based on derivatisation with 2-chloro-1-methylquinolinium tetrafluoroborate (Bald & Glowacki 2001) and separation and quantification by ion-pairing reversed-phase liquid chromatography originally developed for human urine (Kusmierek & Bald 2007) . Details of the procedure used for chicken tissues, eggs and embryos have been described elsewhere (G Chwatko, V M Darras & E Bald, Personal communication 2013) .
Determination of T 4 and T 3 levels
T 4 and T 3 levels in maternal and embryonic tissues were measured following extraction as described previously in detail (Reyns et al. 2002 (Reyns et al. , 2005 . Typical recoveries of extracted THs ranged from 55 to 75% for T 3 and from 40 to 60% for T 4 . The T 3 RIA had a detection limit of 2 fmol and an intra-assay variability of 2.2%. The T 4 RIA had a detection limit of 5 fmol and an intra-assay variability of 2.8%. For the T 3 RIA, cross-reactivity with T 4 was 0.1-0.5%, whereas for the T 4 RIA, cross-reactivity with T 3 was 3.5%. Hormone levels are expressed as picomole per gram tissue.
T 4 and T 3 levels in plasma were measured using the same RIA system without extraction, using a standard in hormone-free serum, and results are expressed as picomole per millilitre plasma.
Thyroid glands were homogenised in 500 ml ice-cold barbital buffer (0.05 M, pH 8.6) using a Glass/Teflon Potter tissue grinder system. This step was followed by further ultrasonic homogenisation (2!25 s). Homogenates were then centrifuged and supernatants were transferred into new tubes. Part of the supernatants was directly frozen and stored at K20 8C. For enzymatic degradation of thyroglobulin by addition of 150 ml protease (Sigma P-5147, 6.25 mg protease and 3.13 mg 2-thiouracil in 10 ml Tris-HCl buffer, 0.75 M and pH 8.8) and 15 ml toluol, 150 ml of the supernatants were used. Tubes were stoppered and incubated for 2 days in a shaking water bath at 37 8C.
Finally, tubes were placed in boiling water for 2 min to inactivate the pronase enzyme, snap frozen and stored at K20 8C. Dilutions of untreated homogenates (free hormone levels) and enzymatically digested homogenates (total hormone levels) were analysed by RIA, and free and total hormone contents were calculated per thyroid gland.
RT and quantitative PCR
Total RNA was isolated using TRIzol reagent (Life Technologies) and treated with DNase I (Life Technologies) to remove residual genomic DNA. Total RNA was reversetranscribed using SuperScript III Reverse Transcriptase and Oligo(dT) 12-18 primers (Life Technologies). Real-time PCR was performed using a thermal cycler, StepOnePlus Real-Time PCR Systems (Life Technologies), with Fast SYBR Green Mastermix (Life Technologies) and 300 nM of each primer as listed in Table 1 . Non-template and water controls were used to detect non-specific amplification. Each experimental and standard sample was analysed in duplicate. Relative expression values were calculated based on the standard curve with the StepOne Software (Life Technologies) using a 1:5 dilution series of pooled cDNA as the standard. The expression data were analysed using the qBase PLUS Software (Biogazelle, Zwijnaarde, Belgium). Two reference genes were used for normalisation: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophilin for adult hens and GAPDH and b-actin for embryos.
Deiodinase enzyme assays
In vitro deiodination activities were determined in microsomes obtained from maternal liver and kidney and in homogenates of the different maternal and embryonic CAC TGC TGT GCT TTC AAG AAC TG  119   NIS  XM_429095  CAC CAC GGA GGC TGAT GTT  GCG CAG CCA CCG TGA T  75  TTF1  NM_204616  GCC GTT CTC CTG TTG CAT CT  GAA CAT TTA GCC AGC ATG ATC CA  126  TPO  AM167549  TTC CGA TAA AGG TAA CAA CCA ATG CAG TGC CAC ATG CAG GAG AT  87  TG  XM_003640868  CAA CGT TTT CCA GGC CAT TG  CCA GTG ATT GGC CAT GTT TAT G  80  b-Actin  NM_205518  ATG GCT CCG GTA TGT GCA A  TGT CTT TCT GGC CCA TAC CAA  120  GAPDH  NM_204305  GAA GCT TAC TGG AAT GGC TTT CC  GAT ATC ATC ATA CTT GGC TGG TTT CTC  97  Cyclophilin A  NM_001166326  GGC TAC AAG GGC TCC TGC TT  CCG TTG TGG CGC GTA AA  77 brain regions as described in detail earlier (Darras et al. 1992 , Reyns et al. 2005 . In the D1 activity test, the incubation mixture contained 0.1 mg of protein/ml and 1 mM rT 3 containing 50 000 c.p.m. of radiolabelled [ 125 I]-rT 3 , and tubes were incubated at 37 8C for 30 min. D2 activity was assayed in a similar way by incubating 1 mg of protein/ml and 1 nM T 4 containing 50 000 c.p.m.
[ 125 I]-T 4 at 37 8C for 120 min. A second mixture was prepared with 100 nM T 4 to assess possible interference of D1 activity. Only when iodide production was absent or minimal in the presence of 100 nM T 4 , enzyme activity using 1 nM T 4 was considered to be the true D2 activity. In the D3 activity test, the incubation mixture contained 1 mg of protein/ml and 1 nM T 3 containing 150 000 c.p.m. [ 125 I]-T 3 as well as 1 mM rT 3 and 0.1 mM 6n-PTU to block possible D1 interference. The mixture was incubated for 120 min at 37 8C. Activities were calculated as picomol (D1) or femtomol (D2 and D3) of hormone deiodinated per milligram protein and per minute.
Statistical analysis
All data comparisons between the control group and the MMI group for the given age and tissue were done by Student's unpaired t-test. Comparisons with P values !0.05 were considered significantly different.
Results
MMI levels in maternal and embryonic tissues
We measured MMI levels in the hens, eggs and embryos of the MMI-treated groups to evaluate maternal transfer to the embryos. As not only reduced MMI but also its metabolites may have adverse effects on embryonic development, we used a method allowing discrimination between the total amount of MMI (including oxidised forms) and that of reduced MMI (the anti-thyroid active form). From weeks 10 up to 16 of treatment, the average levels of reduced MMI were 11.0G0.6 mg/g wet weight for egg yolk (76% of total MMI level) and 12.8G0.7 mg/g wet weight for egg white (95% of total MMI level; meanGS.E.M. for a total of 12 samples). MMI levels in maternal and embryonic tissues are given in Table 2 . As expected, the highest levels were found in the thyroid gland of adult hens. In these animals, reduced MMI levels were also clearly higher in the peripheral tissues (plasma and liver) than in the brain. A different result was found in embryos where reduced MMI levels were similar in the peripheral tissues and brain. E6 embryos had the highest levels and almost all MMI was present in the reduced form. Total MMI concentrations were comparable at E14 and E18, but the percentage present as reduced MMI was clearly lower at E18 than at E14. However, reduced levels in the embryonic brain remained higher than the levels in the adult brain. Owing to the small size of the embryonic thyroid gland, we were not able to determine MMI levels in this tissue.
Effects on maternal thyroid gland activity
Sixteen weeks of MMI treatment strongly increased the size of the thyroid gland (Table 3 ). The expression of a number of genes involved in thyroid gland activity was significantly affected, with a decrease in the mRNA levels of thyroid transcription factor 1 (TTF1 (NKX2-1)) and thyroglobulin (TG) and a significant increase in the mRNA levels of sodium/iodide symporter (NIS (SLC5A5)), thyroid peroxidase (TPO) and thyrotropin receptor (TSHR) (Fig. 1 ).
The amount of T 4 per weight unit of the thyroid gland was more than 100-fold reduced following MMI treatment, and despite the substantial increase in the size of the thyroid gland, both total and free T 4 contents were about tenfold decreased. The amount of T 3 per weight unit was far less affected, and in combination with the higher weight of the thyroid gland, this resulted in a twofold increase in total T 3 content and a sevenfold increase in free T 3 content (Table 3) .
TH levels in maternal and embryonic tissues
Blood samples were collected from hens every 2 weeks throughout the treatment period. Circulating T 4 levels in the MMI-treated hens showed a steady decrease until 6 weeks of treatment when they stabilised around 50% of the control levels. Plasma T 3 content was mildly decreased at 10 and 14 weeks of treatment, but remained unchanged at all other time points (data not shown).
T 4 and T 3 levels in maternal tissues are shown in Fig. 2 . T 4 levels were strongly decreased in the plasma, liver, kidney and different brain regions of the MMI-treated hens, except in the diencephalon. While T 3 levels in peripheral plasma, liver and kidney were similar for the control and MMI-treated hens, T 3 content was strongly decreased in the telencephalon and mesencephalon and mildly but not significantly decreased in the diencephalon and cerebellum.
The number of eggs produced by the MMI-treated hens decreased and stabilised around week 8 at 20-25% of the number produced by the control hens. However, the overall quality of the eggs did not change; egg weight, crude energy content, crude protein content and crude lipid content were similar in the MMI-treated and control groups. By contrast, the amount of T 4 and T 3 deposited in the egg yolk was strongly decreased throughout the egg collection period (Fig. 3 ). T 4 levels in E6 embryos were similar in the trunk and head and were surprisingly not decreased by MMI treatment. At this stage, T 3 levels were clearly higher in the head than in the trunk and were significantly lower in the head of MMI embryos (Fig. 3) .
Maternal MMI treatment decreased circulating T 4 levels in E14 and E18 embryos. However, T 4 levels in liver, heart, lung, muscle and different brain regions were not altered (Figs 4 and 5) . The situation was different for T 3 . While plasma T 3 content was not significantly decreased, levels were, in general, clearly lower in both peripheral tissues and brain in MMI embryos at E14. At E18, T 3 levels were still decreased in the brain but no longer in the peripheral tissues (Figs 4 and 5) . 
Expression of TH transporters and deiodinases in maternal and embryonic brain
As MMI treatment clearly affected TH levels in the brain, we measured the mRNA expression of the deiodinases D2 and D3 and the TH transporters OATP1C1 (SLCO1C1) and MCT8 (SLC16A2). Expression was measured in the telencephalon, diencephalon, mesencephalon, cerebellum and hindbrain of the control and MMI-treated hens, but no significant changes were observed. The expression of these four genes was also measured in the telencephalon, diencephalon and mesencephalon of E6 and E14 embryos. No significant changes were found at E6. At E14, the expression of D2 and MCT8 was decreased by respectively 34 and 27% (P!0.05) but only in the diencephalon.
Deiodinase activity in maternal and embryonic tissues
MMI treatment did not significantly affect D1 or D3 activity in maternal liver and kidney, but it strongly increased D2 activity in all regions of the maternal brain (Table 4) . Moderate but significant increases were also observed in the diencephalon and mesencephalon of E14 embryos. No increases were found in the embryonic brain at E6, where D2 activity was even significantly lower in embryos from MMI eggs compared with the controls (Table 4 ).
The only significant change in D3 activity was found in the adult brain where activity was decreased in the telencephalon of the MMI-treated hens (0.597 G0.036 fmol T 3 deiodinated/mg protein per min vs 0.766G0.068 in the controls, P!0.05).
In order to determine whether the presence of MMI as such is able to decrease the efficiency of T 4 -to-T 3 conversion, we also tested D2 activity in the brain homogenates of a number of control embryos in the presence or absence of 20 mg MMI/ml, a concentration corresponding to the highest level observed in tissues (maternal thyroid, 20 mg/g wet weight). The addition of MMI to the homogenates did not alter in vitro D2 activity.
Discussion
The anti-thyroid drug MMI can be absorbed from the gastrointestinal tract and it accumulates in the thyroid gland where it inhibits TH synthesis by interfering with the action of thyroid peroxidase (Nagasaka & Hidaka 1976 , Vickers et al. 2012 . It has been shown in humans and rats that MMI is rapidly metabolised and that a major part is excreted via urine (Skellern & Steer 1981 , Hengstmann & Hohn 1985 , Cooper 2005 , Kusmierek & Bald 2007 . Nevertheless, MMI treatment sometimes induces severe side effects such as agranulocytosis and hepatotoxicity (Cooper 2005 , Yang et al. 2012 , indicating that a significant amount of MMI and/or its metabolites is present in extra-thyroidal tissues. We measured the levels of reduced MMI and its oxidised metabolites in hens following 16 weeks of treatment. The dose that we used was relatively high compared with the ones used in medical practice. Circulating levels were about fourfold higher than the average levels reported for humans (Mortimer et al. 1997 ), but relative differences in tissue levels might also apply to humans where tissue data are scarce. As in humans and rats (Marchant & Alexander 1972 , Jansson et al. 1983 , MMI specifically accumulated in the thyroid gland. About sixfold lower levels were present in the liver, mainly in the reduced form. Total levels in the brain were about half of those in the liver, suggesting that the adult brain is somehow better protected. Interestingly, we found clear differences in the proportion of MMI present as oxidised metabolites. This was more than 40% in the mesencephalon and cerebellum, while this was around 10% in the telencephalon, similar to that observed in the peripheral tissues. So far, it remains unclear whether this difference is the result of a higher local metabolism of MMI or a selective uptake related to the tissue composition. The fact that total MMI levels are similar could be an element in favour of the first hypothesis.
The major problem with MMI as well as other thionamides in humans and more precisely in pregnant women is that these compounds are transferred to the developing foetus via the placenta and may harm normal development (Cooper 2005 , Vissenberg et al. 2012 . In birds, essential as well as potentially harmful substances are deposited in the egg and taken up by the embryo during development. Two important conclusions can be drawn from the MMI measurements in chicken embryos. The first one is that although both total and reduced MMI levels in embryonic tissues are gradually decreasing from early towards later stages of development, they always remain above the levels found in the corresponding adult tissues. The second one is that the levels in the embryonic brain are as high as those in the embryonic liver, suggesting that the protective mechanisms possibly present in the adult brain are not yet functional before hatching. Most of the MMI is present in the reduced form, although there seems to be a gradual increase in the percentage of oxidised metabolites, especially in the brain. However, although these metabolites no longer function as anti-thyroid drugs, they can be cytotoxic and therefore may still contribute to the adverse effects of MMI on development (Kedderis & Rickert 1985 , Genter 1998 . When investigating maternal thyroid status, we found that the MMI-treated hens were able to keep up normal plasma T 3 levels despite a 50% decrease in circulating T 4 levels. The same was true for the TH content in the liver and kidney. One possible mechanism would be an increase in the peripheral conversion of T 4 into T 3 by outer-ring deiodination and/or a decrease in T 3 degradation by innerring deiodination. The results of the in vitro D1 and D3 activity tests in the liver and kidney suggest that this is not the case. By contrast, we observed dramatic changes at the level of the thyroid gland. The most obvious one was the huge goitre, which can most probably be explained by a decrease in the negative feedback of T 4 at the level of the pituitary thyrotropes (Huang et al. 2001 , Bianco & Kim 2006 . The increased growth of the thyroid gland was accompanied by a highly increased relative expression of the thyrotropin receptor, the sodium/iodide symporter and thyroid peroxidase, while the expression of thyroglobulin and TTF1 was slightly decreased. This is somewhat different from observations in human thyroid cells and rat FRTL-5 cells cultured in vitro where short-term treatment with MMI increased the expression of thyroid peroxidase as well as thyroglobulin (Leer et al. 1991) . However, recent studies on human thyroid slices have shown that the effect of MMI on the expression of thyroid-specific genes may vary according to treatment dose and duration (Vickers et al. 2012) .
In accordance with the inhibitory effect of MMI on iodine integration into tyrosine, both total and free T 4 contents were strongly decreased. By contrast, long-term MMI treatment resulted in a twofold increase in total T 3 content and a sevenfold increase in free T 3 content. This way the MMI-treated hens could maintain normal T 3 levels by shifting from a predominance of T 3 produced by peripheral deiodination of T 4 to a predominance of T 3 produced within the thyroid gland. A similar mechanism has not been found in pregnant rats where MMI treatment reduced T 4 as well as T 3 levels in plasma, liver and heart, although the relative decrease was smaller for T 3 (Calvo et al. 1990) . This could be a species-related difference, but it is also possible that the treatment period of 7 days in the rat experiment was too short to induce substantial changes in the ratio of T 3 :T 4 content and release of the thyroid gland.
The adaptive mechanism in adult hens seems to be sufficient to maintain T 3 levels in peripheral tissues such as liver and kidney, but not in the brain, which is known to depend heavily on T 4 uptake and local T 4 -to-T 3 conversion by D2 (Silva & Matthews 1984 , Grijota-Martinez et al. 2011 . Despite a clear increase in D2 activity, most brain regions did not succeed in compensating for the reduced supply of T 4 and showed low T 3 levels. This finding illustrates once more that the thyroid status of a specific tissue cannot be simply deduced from the TH levels present in circulation.
A tissue-specific control also seems to be active at the level of the ovary, since both T 4 and T 3 concentrations in the eggs were severely reduced despite the normal plasma T 3 levels. This control occurred independently of the overall protein and lipid contents of the eggs, which were not changed by MMI treatment. The fact that the total number of eggs was reduced confirmed earlier data on the inhibitory effect of hypothyroidism on female reproduction in a number of species including fish, amphibians and humans (Van der Geyten et al. 2001 , Krassas et al. 2010 , Carr & Patino 2011 .
Maternal MMI treatment clearly has an effect on tissue TH availability in developing embryos but, surprisingly, predominantly on T 3 . Again, this is not reflected in the circulation since both E14 and E18 embryos from MMI eggs showed significantly reduced plasma T 4 levels, while plasma T 3 content was not significantly different. At E6, T 4 levels in the body of the control and MMI embryos were similar. As at that stage the embryonic thyroid gland is developing but not yet functional, this suggests that the embryo can compensate for the reduced T 4 content in the egg yolk by a more efficient T 4 uptake. The embryonic thyroid gland normally starts contributing to TH availability in the embryo during the second week of incubation and the effects observed at E14 and E18 should therefore be interpreted as the combined result of the reduced TH content in the yolk and the inhibition of embryonic thyroid gland activity by MMI taken up by the embryo. As in adult hens, the brain of E14 and E18 embryos from MMI eggs had clearly lower T 3 levels but without a decrease in T 4 content, a combination that is difficult to explain. The possibility of a direct inhibitory effect of MMI on D2 activity in brain homogenates was tested, but it proved to be negative. In vitro D2 activity tests on the brain of E14 embryos showed that the amount of active enzyme was higher in the diencephalon and mesencephalon of MMI embryos compared with the controls, indicative of a compensatory response. This response was, however, not present in all brain regions, and it was less pronounced than the strong response in the brain of adult hens. Together with the fact that there was no compensatory increase in D2 activity in the brain at E6, this confirms earlier observations that the typical compensatory response of deiodinases to altered TH availability is not yet mature in young embryos/foetuses (Ruiz de Ona et al. 1988 , Gereben et al. 2008 , Sharlin et al. 2010 , Van Herck et al. 2012 . The single changes found in D2 and MCT8 mRNA in different brain regions of E14 embryos are also not in line with a compensatory response at the level of gene expression and rather point to a delay in the normal ontogenetic expression pattern of these genes in hypothyroid MMI embryos (Geysens et al. 2012 , Van Herck et al. 2012 . The fact that hypothyroidism as such did not change the mRNA expression of the deiodinases in the embryonic as well as adult brain is in agreement with literature data from embryonic and post-hatch quail exposed to perchlorate (Chen et al. 2008 (Chen et al. , 2009 .
One more interesting observation is that T 3 availability was reduced not only in the brain but also in the peripheral tissues of E14 embryos, while this was no longer the case at E18. During the second half of embryonic development, the relative contribution of the embryonic thyroid gland to total TH availability increases over time and is therefore higher at E18 where the hypothalamopituitary-thyroid axis is almost completely mature. As in adult hens, the embryonic thyroid gland may have increased its relative release of T 3 and this is in line with the fact that at E18 free T 3 content was increased in the thyroid gland of MMI embryos. The slower maturation of the thyroid axis in rodents compared with chickens may also help to explain why in rat foetuses from MMI-treated dams both T 4 and T 3 contents are decreased in the peripheral tissues and brain, similar to the situation in the dams themselves (Calvo et al. 1990) .
Taken together, our data show that long-term MMI treatment of hens severely reduces T 4 production in the thyroid gland but induces a relative increase in thyroidal T 3 content. As a result, peripheral tissues can maintain normal T 3 levels, but the brain is clearly hypothyroid. As in mammals, the treatment leads to the maternal transfer of MMI and its oxidised metabolites to the developing embryo. Levels in embryonic tissues are relatively high, especially at the early stages, and MMI and/or its oxidised metabolites may therefore have cytotoxic effects on all developing tissues including the brain. Long-term MMI treatment also reduces TH availability in the egg yolk, resulting in lower T 3 availability in the early embryonic brain. At later stages, the maternally derived MMI also disturbs embryonic thyroid gland function. Combined with the lower TH content of the yolk, this results in a reduced T 3 content in the peripheral tissues and brain of 14-day-old embryos and in the brain of 18-day-old embryos. We can conclude that the maternal transfer of MMI and its metabolites to the embryo can be harmful for embryonic development, in particular, for the brain, by a combination of anti-thyroidal and possibly local cytotoxic effects, an observation that may also be of relevance to the human situation.
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